Book Value per Share: iCAD Corp (ICAD)

Public company logo of iCAD, Inc. (ICAD)

iCAD, Inc. (ICAD) generates revenue through the implementation of ProFound AI for breast cancer diagnostics and therapy. The scalability of the cloud-based SaaS service enables clinics to integrate without capital expenditures. The net asset value per share visualizes this efficiency, where 1.14 determines the latest valuation metric. Stringent FDA standards and B2B software integration ensure steady license growth and market protection.

iCAD Corp (ICAD) - Accounting Value per Share from 07/04/2022 to 08/02/2025

Summary analytical data breakdowns for iCAD Inc. (ICAD)

- price and consensus price forecast:
Stock Price iCAD Corp|ICAD - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization iCAD, Inc.|ICAD - Business Value
- book capitalization data:
Book Value per Share iCAD|ICAD - Company Net Assets|Market Capitalization to Book Value Ratio icadmed.com|ICAD - Company Total Assets
- debt and liquidity data:
Debt to Equity iCAD, Inc.|ICAD - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital iCAD Corp|ICAD - Company Total Debt|Debts to Book Capitalization iCAD, Inc.
Analysis of all company metrics:icadmed.com, ICAD
Manufactured product of iCAD Inc.

Book value per share reflects the portion of equity attributable to a single security and serves as an indicator of the business's intrinsic value regardless of market fluctuations. By analyzing the book value per share trend, an investor assesses the financial stability of iCAD, Inc. (ICAD) amid the slow adoption of AI systems in medicine and the transition to a subscription model to protect margins.

Competitor analysis for iCAD, Inc.

BeiGene Corp - Book Value per Share|HALO - Book Value per Share|Book Value per Share Revolution Medicines|ascentage.com (AAPG) - Equity per Share|Book Value per Share CGON|Accounting Value per Share UroGen Pharma Ltd|Book Value per Share BCAX|Book Value per Share PSNL (Personalis Genomics)|ERAS - Net Assets per Single Share|Equity per Share delcath.com DCTH|YMAB: Book Value per Share|AURA - Accounting Value per Share|Book Value per Share CADL|ARAY (Accuray, Inc.) - Net Asset Value per Share|SLS - Net Assets per Single Share|Accounting Value of a Share actuatetherapeutics.com (ACTU)|Citius Oncology (CTOR) - Accounting Value per Share|Accounting Value of a Share tuhurabio.com (HURA)|Protara - Book Value per Share|FATE - Accounting Value per Share|Aadi Bio - Accounting Value per Share|TCRX: Book Value per Share|Net Assets per Single Share championsoncology.com CSBR|XBiotech (XBIT) - Accounting Value of a Share|Book Value per Share CVM (CEL-SCI Corp.)|Net Asset Value per Share OS Therapies, Inc.|RADX (Radiopharm Theranostics Limited) - Book Value per Share|Net Assets per Share artivabio.com (ARTV)|Adlai Nortye - Book Value per Share|Accounting Value per Share Veru Inc VERU|Tempest Tx - Book Value per Share|XLO - Book Value per Share|Book Value per Share renovarobio.com|Equity per Share Mural Oncology|KAPA - Accounting Value per Share|Accounting Value of a Share OnKure|GDTC (CytoMed Therapeutics) - Book Value per Share|Net Assets per Share CRIS (curis.com)|APLM - Net Assets per Single Share|Equity per Share tharimmune.com THAR|ADVB: Book Value per Share|Genprex Inc. (GNPX) - Accounting Value per Share|calidibio.com - Accounting Value per Share|Sunshine Biopharma Inc. (SBFM) - Net Assets per Share|XBIO: Book Value per Share|Net Assets per Share salariuspharma.com|Book Value per Share PPBT (Purple Biotech Ltd.)|Accounting Value per Share aoncology.com (AONC)|Book Value per Share BGNE (BeOne Medicines)|Book Value per Share Checkpoint Therapeutics Inc CKPT|Elevation Oncology, Inc. (ELEV) - Book Value per Share|IKNA - Equity per Share|NTBL (Notable Labs) - Book Value per Share|Viracta Therapeutics, Inc. (VIRX) - Accounting Value per Share|MOR (MorphoSys Corp) - Book Value per Share|Book Value per Share NAYA|Net Assets per Single Share Ascentage Pharma Group AAPGV